Green Cross’s Hepabig-Gene gets orphan drug designation

Green Cross Corp. said last Thursday that Hepabig-Gene, a recombinant antibody for hepatitis B, was designated as an “orphan drug” by the United States Food and Drug Administration (FDA).

The FDA provides orphan drug designation to drugs that seek to treat rare diseases or conditions for which there may be few adequate therapies. Orphan drug designation is intended to encourage companies to ...